Astex Pharmaceuticals, Inc.
Astex Pharmaceuticals, Inc. is committed to the fight against cancer. Astex is developing a proprietary pipeline of novel therapies for the treatment of hematologic malignancies and solid tumors. These include the oral hypomethylating agent decitabine and cedazuridine (ASTX727), for the treatment of myelodysplastic syndromes and acute myeloid leukemia; and tolinapant (ASTX660) for the treatment of T-Cell lymphomas. Astex is a member of the Otsuka group of companies, which includes Taiho Pharmaceutical and Taiho Oncology. Subject to regulatory approvals, Astex’s products will be commercialized in the US and Canada by Taiho subsidiaries, and in the rest of the world by Otsuka subsidiaries.